Document Detail

Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia.
MedLine Citation:
PMID:  18996784     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To determine the prevalence of valvular heart disease in a cohort of patients taking cabergoline for the management of hyperprolactinemia.
METHODS: A retrospective review of medical records identified patients with hyperprolactinemia who underwent evaluation at Vanderbilt University Medical Center between January and June 2007. The medical records of those patients who were prescribed cabergoline and who underwent elective echocardiography were reviewed for details pertaining to cardiac valvular abnormalities and cabergoline use.
RESULTS: Forty-five patients (mean age, 41 +/- 10 years [SD]) taking 0.91 +/- 0.96 mg of cabergoline per week for a mean duration of 39 +/- 29 months underwent echocardiography. Abnormalities of the cardiac valves were present in 3 patients (7%): 1 patient exhibited mild mitral regurgitation, 1 patient had focal aortic valve thickening, and 1 patient demonstrated mitral valve thickening. We found no significant difference in either the cumulative dose of cabergoline (P = .800) or the duration of cabergoline therapy (P = .745) between those patients with and those without these echocardiographic abnormalities.
CONCLUSION: We found echocardiographic valve abnormalities in 3 of 45 patients (7%) who had been prescribed cabergoline for the management of hyperprolactinemia. This prevalence of valvular heart disease after approximately 3 years of cabergoline treatment is no different from that previously reported in normal populations as determined by echocardiography.
Jessica K Devin; Vipul T Lakhani; Benjamin F Byrd; Lewis S Blevins
Related Documents :
9436554 - Influence of pulmonic position on durability of bioprosthetic heart valves.
18155514 - Marfan syndrome-diagnosis and management.
11030124 - Organ malperfusion in acute aortic dissection.
17870004 - Gore-tex chordoplasty in degenerative mitral valve repair.
3946924 - Chemiluminescence of lung macrophages and blood leukocytes in sarcoidosis.
17622884 - Bioavailability of oral fluconazole in critically ill abdominal trauma patients with an...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists     Volume:  14     ISSN:  1934-2403     ISO Abbreviation:  Endocr Pract     Publication Date:  2008 Sep 
Date Detail:
Created Date:  2008-11-10     Completed Date:  2009-04-20     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  9607439     Medline TA:  Endocr Pract     Country:  United States    
Other Details:
Languages:  eng     Pagination:  672-7     Citation Subset:  IM    
Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cohort Studies
Ergolines / adverse effects*,  therapeutic use*
Heart Valve Diseases / chemically induced*
Hyperprolactinemia / drug therapy*
Middle Aged
Reg. No./Substance:
0/Ergolines; LL60K9J05T/cabergoline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prevalence of osteoporosis in ambulatory postmenopausal women from a semiurban region in Southern In...
Next Document:  Influence of lower cutoff values for 100-g oral glucose tolerance test and glycemic profile for iden...